Drug Delivery To Cns; Various Approaches For Parkinson's Disease Management: An Update

Research Article
Manoj Kumar Katual and Harikumar S.L
Nigrostriatal dopaminergic neurons, Neuro-degenerative disorders, Dyskinesia, Neurotoxins, SLN, Frozen addict

Parkinson’s disease is the major threat to the population of 1 among 100 in U.S. Parkinson’s disease is occurring due to dopamine deficiency, which is caused by the degeneration of nigrostriatal dopaminergic neurons. This causes the major clinical motor symptoms of Parkinson’s disease. Though the treatment methods are available, the treatment of predominantly non-motor feature are remain a challenge which is caused by the degeneration of non-dopaminergic neurons. The review focused on the challenges and important therapeutic advancements of the disease. This article opens the view on different approaches for dopaminergic, non-dopaminergic drugs for Parkinson’s disease and use of novel drug delivery systems such as nanoparticle drug delivery. The motor complications arise from the existing therapy can be controlled by various therapeutic approaches and drug delivery systems. The non motor symptoms of the diseases (Commonly known as Frozen Addict) were poorly recognized and inadequately treated. However, attention is now being focused on the non-motor symptoms, which may be the ray of hope in the treatment of disease in new dimensions. This is the area which arose less concentrated in the previous decades the need for newer and effective agents in the treatment. Still the extensive research has to be focused further. The non pharmacological treatments also may explore in the near future like PD vaccine, Cell transplantation, Gene therapy and surgical methods. The drug delivery system such as TDDS & Nanoparticles drug delivery systems also contribute more for the novel approaches to eradicate the killer disease in coming decades.